



17 February 2026

Medicine Supply Alert Notice

Lanreotide 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml solution for injection pre-filled syringes

Priority: Level 2*

Valid until: end of June 2026

Issue

1. Advanz Pharma's lanreotide 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes are unavailable until at least the end of June 2026.
2. New patient referrals for Advanz Pharma's lanreotide 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes will not be accepted during this period.
3. Ipsen's lanreotide (Somatuline Autogel®) 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes remain available and can support increased demand.
4. Ipsen's lanreotide (Somatuline Autogel®) pre-filled syringes are available via an Ipsen manufacturer-sponsored homecare scheme through specific homecare providers.

Advice and Actions

5. Health Board pharmacy procurement teams, working with the appropriate clinical specialists, hospital pharmacy teams and their pharmacy homecare lead, should:
 - not initiate new patients on any strength of Advanz Pharma's lanreotide solution for injection pre-filled syringes until the shortage resolves;
 - prescribe Somatuline Autogel® (lanreotide) solution for injection pre-filled syringes for new patient initiations; and
 - identify all patients currently established on Advanz Pharma's lanreotide pre-filled syringes who do not have sufficient supply during this period, and where appropriate, contact the relevant homecare provider and issue a new prescription for Ipsen's lanreotide (Somatuline Autogel®) (see additional information section below).
6. Where the supply route is via primary care, the following actions should be taken:
 - prescribers should ensure prescriptions are written generically for the appropriate strength of lanreotide solution for injection pre-filled syringes and if necessary engage with secondary care colleagues to advise on clinically appropriate alternatives if appropriate;
 - community pharmacists should substitute any prescriptions for Advanz Pharma's lanreotide with the appropriate strength of Somatuline Autogel® (lanreotide) solution for injection pre-filled syringes and endorse the prescription; and
 - community pharmacists should ensure that administration training is offered where required, to facilitate safe transition to any alternative device.

7. Homecare providers should:

- ensure appropriate homecare medicines service contracts are in place with all relevant clinical referring centres to support the service requirements for Ipsen's lanreotide (Somatuline Autogel®) pre-filled syringes;
- identify patients currently prescribed Advanz Pharma's lanreotide solution for injection pre-filled syringes who do not have sufficient supplies;
- engage with the relevant Health Boards to request a new prescription for a clinically appropriate alternative for affected patients, where appropriate;
- engage with the relevant Health Board to ensure that manufacturer commissioned, nurse-led administration training and ongoing administration is offered where required, to facilitate safe transition to the alternative device; and
- notify patients of any changes to their medicines or delivery schedules, in line with agreements made with the Health Board.

Additional Information

Homecare provision

8. Sciensus currently provide generic lanreotide 60 mg/0.5 ml, 90 mg/0.5 ml, and 120 mg/0.5 ml solution for injection pre-filled syringes via Advanz Pharma's manufacturer-commissioned homecare service.
9. Sciensus has confirmed that it can support a switch to Ipsen's lanreotide (Somatuline Autogel®) via Ipsen's manufacturer-commissioned homecare scheme and can facilitate these switches with minimal impact on Health Boards. The Health Boards are encouraged to contact their designated Sciensus homecare contact for further information or support.
10. Sciensus has also advised that, once patients have been switched to the Ipsen product and homecare scheme, they will only revert patients to Advanz Pharma's lanreotide when sufficient accessible stock is available within the network and following express direction from the Health Board.

11. Links to further information

- [BNF Lanreotide](#)
- [SmPC Lanreotide](#)

Specialist Pharmacy Service (SPS) website

12. The UK Department of Health and Social Care (DHSC) in conjunction with the Specialist Pharmacy Service (SPS) have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.
13. Prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland are encouraged to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply

issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

14. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).